Advertisement FDA approves two higher dosage strengths of Orexo's ZUBSOLV - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves two higher dosage strengths of Orexo’s ZUBSOLV

Orexo has received approval from the US Food and Drug Administration (FDA) of two higher dosage strengths of ZUBSOLV (buprenorphine/naloxone CIII sublingual tablet) for maintenance treatment of opioid dependence.

The new dosage strengths are 8.6 mg/2.1 mg and 11.4 mg/2.9 mg buprenorphine/naloxone CIII sublingual tablets. The 8.6 mg/2.1 mg dosage strength is expected to be launched early 2015 and the 11.4 mg/2.9 mg strength later in 2015.

The new dosage strengths complement the existing strengths of 5.7 mg/1.4 mg and 1.4 mg/0.36 mg tablets and enable patients to receive their optimal dose in one tablet.

The new strengths are made with the advanced, proprietary sublingual tablet formulation in ZUBSOLV providing higher bioavailability, a fast dissolve time, small tablet size, and menthol flavor.

"Orexo remains fully committed to advancing the treatment of opioid dependence. During the summer, we received positive data from the largest clinical trials ever conducted in this disease area. Today, we are proud to announce that the FDA has approved two additional dosage strengths of ZUBSOLV. These higher dosage strengths will allow more patients to get the right dosage in only one tablet and thus reduce the need to combine different dosage strengths. This will improve patient convenience and adherence while reducing their out-of-pocket cost as only one co-pay will be required," said Nikolaj Sørensen, CEO and President of Orexo .

The advanced formulation provided by ZUBSOLV meets the needs expressed by patients, such as improved taste and fast dissolve time.

Meeting patient needs may have the potential to improve patient adherence, thus reducing relapse rates and improving successful patient outcomes.

ZUBSOLV is the only opioid dependence treatment option available in the highest level of child resistant, unit dose, F1 packaging, designed to reduce the chance of unintended pediatric exposure.